LLY · Eli Lilly and Co
Price
Snapshot
50 fields · last close| Market Cap | $1.09T |
| P/E | 40.31 |
| Float | 939.7M |
| Beta | 0.43 |
| Volatility | 10.7% |
| Exchange | NYSE |
| Sector | Pharmaceuticals |
| Cap tier | Mega cap |
| Macro sensitivity | Low |
| Clavix score | 71 |
| Price | 1,143.64 |
| Change | −1.38% |
| Prev Close | 1,159.60 |
| Open | 1,170.00 |
| Day Low | 1,137.50 |
| Day High | 1,171.66 |
| Avg Vol | 3 |
| Avg $ Vol | $2.92B |
| 52W High | 1,292.65 |
| 52W Low | 712.05 |
| 52W Pos | 74.3% |
| From High | −11.53% |
| From Low | +60.61% |
| Max DD 1Y | −23.31% |
| Spread | 0.10% |
| Liquidity | Deep |
| SMA 20 | −5.05% |
| SMA 50 | −3.98% |
| SMA 200 | +7.62% |
| RSI (14) | 43.3 |
| Vol 30D | 35.1% |
| Vol 90D | 36.3% |
| 1Y Range | 712–1,293 |
| Daily bars | 506 |
| Perf Week | −1.40% |
| Perf Month | −0.88% |
| Perf Quarter | +3.05% |
| Perf Half Y | +17.93% |
| Perf Year | +57.16% |
| Perf YTD | +5.86% |
| Prev Day | −1.38% |
| Clavix | B |
| Debt / Eq | 1.60 |
| Curr Ratio | 1.58 |
| Int Cover | 35.7× |
| FCF Margin | 15.5% |
| Rev Growth | +47.7% |
| Profit | Profitable |
| Leverage | High |
| Sector rank | 10 / 15 |
What LLY does
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally.
The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.
It also provides oncology products, such as Cyramza for the second-line treatment of gastric cancer or gastro-esophageal junction adenocarcinoma; Erbitux for colorectal cancers and head and neck cancers; Inluriyo for breast cancer; Jaypirca for chronic lymphocytic leukemia or small lymphocytic lymphoma; Retevmo for the treatment of metastatic NSCLC; TYVYT for classic hodgkin’s lymphoma; and Verzenio for breast cancer.
In addition, the company offers immunology products, which include Ebglyss for severe atopic dermatitis; Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Omvoh for ulcerative colitis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis.
Further, it provides Emgality for migraine prevention and episodic cluster headache, as well as Kisubla for symptomatic Alzheimer’s disease.
The company has collaborations with Boehringer Ingelheim Pharmaceuticals, Inc. for the Jardiance product family; and F.
Hoffmann-La Roche Ltd and Genentech, Inc. for lebrikizumab, as well as license agreements with Almirall, S.A. for Ebglyss; and Chugai Pharmaceutical Co., Ltd for orforglipron; strategic collaboration with Ascidian Therapeutics for development of therapies for undisclosed monogenic kidney diseases; and BioArctic AB (publ) for new treatment.
Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Clavix risk grade
regraded every trading dayLLY grades B, 71 of 100. Steadiest on Macro Resilience (70), most exposed on News Sentiment (23, weak). 1 of the 4 weighted dimensions sit above the Pharmaceuticals median. Ranks 10 of 15 in Pharmaceuticals by Clavix score.
How rough the ride is
| LLY | Pharmaceuticals median | |
|---|---|---|
| Betavs the overall market · lower is steadier | 0.43 | 0.43 |
| Volatilityannualized | 10.7% | 10.7% |
| Max drawdown, past yearworst peak-to-trough fall | −23.3% | — |
| Typical daily movemedian absolute daily change | 1.26% | — |
| Days beyond ±3%of the last 252 sessions | 3413% | — |
How its days are spread
Daily returns over the last 252 sessions in 1% bins. Moves beyond ±6% land in the end bins.
52-week range
The bar runs from the lowest to the highest close of the last 252 sessions; the marker is the latest close.
Drawdown from the 1-year peak
Percent below the running high over the last 12 months. Zero is a fresh high.
Market sensitivity
| LLY | Pharmaceuticals median | |
|---|---|---|
| Beta to the markethow much it swings with the S&P 500 · lower is safer | 0.43 | 0.43 |
| Macro sensitivityrate, dollar and credit exposure bucket | Low | Low67% of 15 |
Where it sits on the macro scale
Low means rates, the dollar and credit spreads barely move it. Very High means they drive a large share of its swings. The counts are how many Pharmaceuticals names sit in each bucket.
Where it ranks in its sector
Rank by Clavix score within the sector. Right is the top of the sector.
Price performance
| LLY | |
|---|---|
| 1 week | −1.4% |
| 1 month | −0.9% |
| Year to date | +5.9% |
| 1 year | +57.2% |
Context for the rank, not itself a risk measure.
Recent coverage, scored
| LLY | |
|---|---|
| Articles scoredthe most recent scored coverage, up to 30 | 30since 27 Aug |
| Average score0 most bearish, 100 most bullish | 68 |
| Bullish · bearisharticles above 60 · below 40 | 25 · 2 |
| Directionarticles whose tone is improving vs worsening | 25 ↑ 2 ↓ |
Where the article scores land
Each bar is a 10-point band of article scores. Below 40 reads bearish, above 60 bullish.
Balance sheet, against the sector
The shaded band is the middle half of the 15 Pharmaceuticals names Clavix covers; the tick is the sector median.
Growth
| LLY | |
|---|---|
| Revenue growthyear over year | +47.7% |
Financial Health is shown but does not count toward the grade. Why
0–100, higher is safer. The tick on each bar is the Pharmaceuticals median. Click a dimension for the evidence behind it. Financial Health is shown but does not count toward the grade.
Against Pharmaceuticals
15 companies| Metric | LLY | Sector spread | Median |
|---|---|---|---|
| Beta | 0.43 | 0.43 | |
| Volatility | 10.7% | 10.7% | |
| Debt / equity | 1.60 | 0.94 | |
| Current ratio | 1.58 | 1.86 | |
| FCF margin | 15.5% | 20.8% | |
| Interest coverage | 35.7× | 5.9× |
Recent news
most recent scored articles · the chip is the article’s score · click to openEli Lilly's tirzepatide (sold as Mounjaro for diabetes and Zepbound for weight loss) is showing promise in treating autoimmune diseases, according to the article. If study results hold up, the drug could win approval to be sold for additional medical uses and gain broader insurance coverage.
Eli Lilly announced a major acquisition, part of a broader deal spree in which the company has bought roughly 26 businesses since 2023. The article notes that sales of its GLP-1 drug (a popular class of diabetes and weight-loss treatments) are funding the purchases.
Eli Lilly reported one of the biggest quarters in Big Pharma history, yet its stock trades below its 52-week high. The article suggests the company's pipeline and valuation could drive further gains from here. No specific financial figures or drug developments were provided in the article.
Eli Lilly announced its 10th acquisition of 2026, called the Merida Deal, adding to its immunology drug pipeline. The article frames this as part of a broader effort to build new growth areas outside the company's GLP-1 weight-loss and diabetes franchise.
Eli Lilly announced on Aug. 31 its intent to acquire Merida Biosciences for $2.875 billion. The article suggests the deal signals LLY's interest in expanding beyond its current GLP-1 obesity franchise, but provides few details about what Merida does or the strategic rationale.
Nearest peers by size
Pharmaceuticals| Ticker | Company | Grade | Mkt cap | P/E | Beta | |
|---|---|---|---|---|---|---|
| JNJ | Johnson & Johnson | A- | $671.0B | 31.85 | 0.21 | Compare |
| MRK | Merck & Co Inc | B+ | $375.8B | 116.50 | 0.14 | Compare |
| AZN | AstraZeneca PLC | B+ | $185.7B | 24.00 | 1.39 | Compare |
| PFE | Pfizer Inc | A- | $164.2B | 37.74 | 0.27 | Compare |
| BMY | Bristol-Myers Squibb Co | B+ | $139.1B | 14.87 | 0.19 | Compare |
| RPRX | Royalty Pharma PLC | A | $36.73B | 45.07 | 0.38 | Compare |
| ZTS | Zoetis Inc | B | $31.87B | 12.03 | 0.69 | Compare |
| VTRS | Viatris Inc | B+ | $20.71B | — | 0.91 | Compare |
You just read one holding. Clavix reads the whole portfolio.
Every position you own, graded on the same five dimensions, with an alert when a grade moves. Three months free on iPhone.